Zura Bio furnishes August 20, 2025 press release

Zura Bio Limited filed a current report to furnish a press release dated August 20, 2025.

Rhea-AI Filing Summary

Zura Bio Limited filed a current report to furnish a press release dated August 20, 2025. The company states that the information in Item 7.01 and Exhibit 99.1 is being provided under Regulation FD and is considered “furnished,” not “filed,” which means it is not subject to certain liability provisions of the Exchange Act unless later specifically incorporated by reference. The filing identifies the press release as Exhibit 99.1 and also includes a cover page interactive data file as Exhibit 104.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Zura Bio (ZURA) report in this 8-K filing?

Zura Bio Limited furnished a press release dated August 20, 2025 as Exhibit 99.1 in a current report, providing information under Regulation FD.

How is the information in Zura Bio’s August 20, 2025 press release treated legally?

The company states that the information in Item 7.01 and Exhibit 99.1 is being “furnished” and not “filed” for purposes of Section 18 of the Exchange Act.

Does Zura Bio consider the August 20, 2025 press release to be material information?

Zura Bio notes that by furnishing the information it makes no admission as to the materiality of any information required to be disclosed solely by reason of Regulation FD.

What exhibits are included with Zura Bio’s August 20, 2025 8-K?

The filing lists Exhibit 99.1, a press release dated August 20, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed Zura Bio’s August 20, 2025 current report?

The report was signed on behalf of Zura Bio Limited by Kim Davis, who is Chief Operating Officer, Chief Legal Officer and Corporate Secretary.

Where is Zura Bio Limited headquartered according to this 8-K?

The company’s principal executive offices are listed as 1489 W. Warm Springs Rd. #110, Henderson, NV 89014.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/20/2025 - 07:03 AM Learn about SEC filing dates

false 0001855644 0001855644 2025-08-20 2025-08-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

Warrants [Member]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 20, 2025

Date of Report (Date of earliest event reported)

Zura Bio Limited

(Exact name of registrant as specified in its charter)

Cayman Islands		001-40598		98-1725736
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1489 W. Warm Springs Rd. #110

Henderson, NV 89014

 (Address of principal executive offices, including zip code)

(702) 825-9872

 (Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Ordinary Shares, par value $0.0001 per share		ZURA		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On August 20, 2025, Zura Bio Limited (“ZURA”, the “Company”) issued the press release attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated August 20, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ZURA BIO LIMITED
Date: August 20, 2025	By:	/s/ Kim Davis
		Kim Davis
		Chief Operating Officer, Chief Legal Officer and Corporate Secretary